12:00 AM
 | 
Mar 24, 2008
 |  BioCentury  |  Finance

HAE movers

HAE movers

HAE movers
A spate of news moved competitors in the race of compounds to treat hereditary angioedema (HAE). Last week, CSL (ASX:CSL) was up 8% after its CSL Behring subsidiary announced interim results from...

Read the full 184 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >